{"anticipatedPostingDate":"2027-03","denomUnitsSelected":"Participants","description":"MRD negativity rate is defined as the proportion of participants with CR or better by investigator and negative MRD (assessed by central lab) per IMWG sequencing criteria at any time from the date of first dose until the first documentation of confirmed PD, death or start of new anticancer therapy, whichever occurs first. 1) CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \\<5% plasma cells in BMA. If the only measurable disease is by serum FLC levels, CR was defined as normal serum FLC ratio of 0.26 to 1.65; 2) Sequencing MRD-negative: Absence of clonal plasma cells by next generation sequencing (NGS) on BMA in which presence of a clone was defined as \\<2 identical sequencing reads obtained after DNA sequencing of BMA using the LymphoSIGHT platform (or validated equivalent method) with a minimum sensitivity of 1 in 10\\^5 nucleated cells.","reportingStatus":"NOT_POSTED","timeFrame":"From treatment initiation till study completion","title":"SSA: Minimal Residual Disease (MRD) Negativity Rate as Per IMWG Criteria- Phase 1b","type":"SECONDARY"}